AMNOG Monitor

G-BA Resolutions.
Clearly analysed.

The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.

AMNOG Monitor – Pharmaceutical data analysis
GBA BMG GKV-Spitzenverband KBV AOK Plus Novartis Bayer Boehringer Ingelheim Lilly MSD BioNTech Alnylam Roche Janssen
GBA BMG GKV-Spitzenverband KBV AOK Plus Novartis Bayer Boehringer Ingelheim Lilly MSD BioNTech Alnylam Roche Janssen
GBA BMG GKV-Spitzenverband KBV AOK Plus Novartis Bayer Boehringer Ingelheim Lilly MSD BioNTech Alnylam Roche Janssen
GBA BMG GKV-Spitzenverband KBV AOK Plus Novartis Bayer Boehringer Ingelheim Lilly MSD BioNTech Alnylam Roche Janssen

Features at a glance

Individual decision at a glance

Key data from all AMNOG decisions, summarized in a compact and structured format.

Interactive analysis

Analyze your own research questions by filtering across more than 120 parameters.

Smart search

Fast, quality-assured search of original documents such as dossiers, GBA decisions, justifications (Tragende Gründe), JCAs, and arbitration rulings.

Price trends and annual therapy cost tracking

Price trends for all AMNOG drugs and appropriate comparator therapies (ACTs) at PZN level and for annual therapy costs. Simulate the price negotiation by weighting current ACT costs, including low-cost generics and biosimilars.

EU-HTA

Integration of EU dossiers and JCAs into the AMNOG-Monitor, including PICOs, study results with effect measures, and comparison with AMNOG procedures.

MFN Tracker

All new FDA approvals with their EU, JCA, and AMNOG status. Key figures on FDA and EMA approvals and on the delay of EU approval since the US most-favored-nation (MFN) order.

Current resolutions

Deucravacitinib (2) - Sotyktu®

Psoriatic arthritis, monotherapy or in combination with methotrexate

Skin diseases no additional benefit (100%)
Blinatumomab (14, reassessment) - Blincyto®

Acute lymphoblastic B-cell leukaemia, adults, MRD-positive, Ph-, CD19+

Oncological diseases no additional benefit (100%)
Blinatumomab (13, reassessment) - Blincyto®

Https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1354/

Oncological diseases considerable additional benefit (100%)
Blinatumomab (12, reassessment) - Blincyto®

Acute lymphoblastic B-cell leukaemia, children aged ≥1 month, high-risk first relapse, Ph-, CD19+

Oncological diseases major additional benefit (100%)
Blinatumomab (11, reassessment) - Blincyto®

Acute lymphoblastic B-cell leukaemia, relapsed/refractory, children ≥ 1 month, after ≥ 2 prior therapies or after allogeneic stem cell transplantation, Ph-, CD19+

Oncological diseases no additional benefit (100%)
Blinatumomab (10, reassessment) - Blincyto®

Acute lymphoblastic B-cell leukaemia, relapsed or refractory, CD19+, adults

Oncological diseases non-quantifiable additional benefit (46%)
Aficamten - Myqorzo®

Hypertrophic obstructive cardiomyopathy

Cardiovascular diseases no additional benefit (100%)
Asciminib (4) - Scemblix®

Chronic myeloid leukaemia, Ph+, CML-CP with T315I mutation, pretreated

Oncological diseases no additional benefit (100%)
Clascoteron - Winlevi®

Acne vulgaris; ≥ 12 years

Infectious diseases no additional benefit (100%)
Clesrovimab - Enflonsia®

Secondary prophylaxis of RSV disease, children during their 1st RSV season

Infectious diseases no additional benefit (100%)
Inotuzumab ozogamicin (2) - Besponsa®

Acute lymphoblastic precursor B-cell leukaemia, relapsed/refractory, after allogeneic stem cell transplantation or after relapse with very high risk or after ≥ 2 prior therapies, CD22+, paediatric patients ≥ 1 year of age

Oncological diseases non-quantifiable additional benefit (100%)
Marstacimab (4) - Hympavzi®

Haemophilia A, ≥ 12 years, with factor VIII inhibitors

Hematopoietic diseases no additional benefit (100%)
Marstacimab (3) - Hympavzi®

Haemophilia B, ≥ 12 years, with factor VIII inhibitors

Hematopoietic diseases no additional benefit (100%)
Nivolumab/Relatlimab - Opdualag®

Https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1335/

Oncological diseases considerable additional benefit (100%)
Pretomanid - Dovprela®

Tuberculosis

Infectious diseases additional benefit considered proven (100%)
Remibrutinib - Rhapsido®

Chronic spontaneous urticaria

Skin diseases no additional benefit (100%)
Dupilumab (12) - Dupixent®

Chronic spontaneous urticaria, ≥ 12 years of age

Skin diseases no additional benefit (100%)
Zolbetuximab (2, reassessment) - Vyloy®

Adenocarcinoma of the stomach or gastro-oesophageal junction, HER2-negative, first-line, combination with fluoropyrimidine- and platinum-containing chemotherapy

Oncological diseases minor additional benefit (56%)
Tovorafenib - Ojemda®

Malignant glioma, low-grade with BRAF fusion or rearrangement or BRAF V600 mutation, after at least 1 prior therapy, ≥ 6 months

Oncological diseases non-quantifiable additional benefit (100%)
Dupilumab (13) - Dupixent®

Chronic spontaneous urticaria, ≥ 2 years to < 12 years

Skin diseases no additional benefit (100%)
Three more EU-HTA procedures started

13. November 2026

Three more EU-HTA procedures started

The European health technology assessment has been started for the following three new oncology active substances:

  • Savolitinib: For the treatment of adult patients with locally advanced or metastatic non-small cell …
Read more →
Fifteen years of AMNOG: evidence base is the strongest driver of added benefit

10. November 2026

Fifteen years of AMNOG: evidence base is the strongest driver of added benefit

At ISPOR Europe 2026 in Vienna (8–11 November 2026), Tomeczkowski et al. presented an analysis of 962 benefit assessment dossiers completed between July 2011 and July 2026. Orphan drugs whose …

Read more →
Location clause under § 130a SGB V

07. November 2026

Location clause under § 130a SGB V

At this year’s “Pharma Trends 2027” conference organised by Forum Institut, Matthias Hiller (CDU), member of the Health Committee of the German Bundestag, discussed the criteria of the planned location …

Read more →
All articles